ClinicalTrials.gg
CompletedNCT04996797ARTEMIS-UCUpdated Sep 1, 2026Results posted

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

A Phase 2 interventional study of Tulisokibart and Companion Diagnostic (CDx) Testing in Ulcerative Colitis, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 88 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Colitis, Ulcerative by Merck & Co., Inc — 2 open to participants now, 3 under way, 2 of them phase 3. Colitis, Ulcerative · Merck & Co., Inc.

Enrollment
5th of 11
178 · median 100
Started
2021
with 1 other
Phase 2
2 of 13
1 open now
Registered
9th of 13
by date

Among the 13 studies in Colitis, Ulcerative by Merck & Co., Inc, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 9th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 13 studies in Colitis, Ulcerative by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colitis, Ulcerative by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC). After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • ARTEMIS-UC
  • ARTEMIS
  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Confirmed diagnosis of ulcerative colitis (UC)
  • Has moderately to severely active UC as defined by 3-component Modified Mayo score
  • Must have dependence or have had no response, insufficient response, loss of response, and/or intolerance to at least one of the following therapies: corticosteroid, , or an approved anti-tumor necrosis factor (anti-TNF), anti-integrin, anti-interleukin 12/23 (anti-IL12/23), Janus kinase (JAK) inhibitor, Sphingosine 1-phosphate receptor (S1PR) modulator.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has diagnosis of Crohn's disease or indeterminate colitis
  • Has current evidence of fulminant colitis, toxic megacolon, bowel perforation, total proctocoloectomy or partial colectomy
  • Has current or impending need for colostomy or ileostomy
  • Has had surgical bowel resection within 3 months before screening
  • Has past or current evidence of definite low-grade or high-grade colonic dysplasia not completely removed
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Cohort 1 Tulisokibart

    Participants who are CDx+ and CDx- will receive tulisokibart administered by intravenous (IV) infusion at 1000 mg on Day 1, Week 0, and 500 mg on the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.

    Drug: Tulisokibart

  • Placebo comparator
    Cohort 1 Placebo

    Participants who are CDx+ and CDx- will receive placebo administered by intravenous (IV) infusion on Day 1, Week 0 and the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.

    Other: Placebo

  • Experimental
    Cohort 2 Tulisokibart

    Participants who are CDx+ will receive tulisokibart administered by intravenous (IV) infusion at 1000 mg on Day 1, Week 0 and 500 mg on the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.

    Drug: Tulisokibart · Device: Companion Diagnostic (CDx) Testing

  • Placebo comparator
    Cohort 2 Placebo

    Participants who are CDx+ will receive placebo administered by intravenous (IV) infusion on Day 1, Week 0 and the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.

    Device: Companion Diagnostic (CDx) Testing · Other: Placebo

Interventions

  • Administered by IV infusion

    Also known as: MK-7240, PRA023

  • DeviceCompanion Diagnostic (CDx) Testing

    PRA023 CDx Genotyping Assay

  • OtherPlacebo

    Placebo administered by IV infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Cohort 1 Achieving Clinical Remission

    The 3-component Modified Mayo Score (MMS) ranges from 0 to 9 and is composed of endoscopic assessment, rectal bleeding (RB), and stool frequency (SF) subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who experienced at least one AE is reported.

    Time frame: Up to ~14 weeks

  3. Percentage of Participants Who Discontinued Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who discontinued due to an AE is reported.

    Time frame: Up to ~14 weeks

  4. Percentage of Participants Who Had One or More Serious Adverse Events

    Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Serious adverse events are defined as: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Life-threatening consequences; urgent intervention indicated, and death. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants experiencing a serious AE are presented.

    Time frame: Up to ~14 weeks

Secondary outcomes

  1. Percentage of Participants in Cohort 1 With Endoscopic Improvement

    The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of the MMS of ≤ 1 with no friability. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  2. Percentage of Participants in Cohort 1 Achieving Clinical Response

    The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined as a reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  3. Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Remission

    The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  4. Percentage of Participants in Cohort 1 With Symptomatic Remission

    RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  5. Percentage of Participants in Cohort 1 With Histologic Improvement

    Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  6. Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Improvement

    Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  7. Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Endoscopic Improvement

    The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of MMS of ≤ 1 with no friability. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  8. Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Response

    The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined by reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  9. Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Symptomatic Remission

    RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  10. Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic Improvement

    Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  11. Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Improvement

    Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  12. Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Healing

    Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  13. Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Healing

    Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  14. Percentage of Participants in Cohort 1 With an Inflammatory Bowel Disease Questionnaire (IBDQ) Response

    IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

  15. Percentage of Participants Who Are CDx+ (Cohorts 1 + 2) Who Had an IBDQ Response

    IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

    Time frame: Baseline and Week 12

07

Results

Posted Jun 27, 2024

Participant flow

Participants with moderately to severely active ulcerative colitis were enrolled.

Induction Period
Participant flow — Induction Period
MilestoneCohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboWeek 12 Responders: OLE 100 mg TulisokibartWeek 12 Responders: OLE 250 mg TulisokibartWeek 26 Responders: OLE 100 mg TulisokibartWeek 26 Responders: OLE 250 mg TulisokibartWeek 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mgWeek 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg
Started68672221000000
Treated68672221000000
Received open-label induction regimen2141812000000
Completed68622220000000
Not completed0501000000
Withdrew: Adverse event0001000000
Withdrew: Physician decision0100000000
Withdrew: Withdrawal by subject0400000000
OLE Period
Participant flow — OLE Period
MilestoneCohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboWeek 12 Responders: OLE 100 mg TulisokibartWeek 12 Responders: OLE 250 mg TulisokibartWeek 26 Responders: OLE 100 mg TulisokibartWeek 26 Responders: OLE 250 mg TulisokibartWeek 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mgWeek 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg
Started00004146312700
Treated00004146312700
Completed000091513600
Not completed00003231182100
Withdrew: Lost to follow-up0000201100
Withdrew: Withdrawal by subject00007710900
Withdrew: Transitioned to a separate extension study0000232471100
OLE Dose Escalation Period
Participant flow — OLE Dose Escalation Period
MilestoneCohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboWeek 12 Responders: OLE 100 mg TulisokibartWeek 12 Responders: OLE 250 mg TulisokibartWeek 26 Responders: OLE 100 mg TulisokibartWeek 26 Responders: OLE 250 mg TulisokibartWeek 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mgWeek 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg
Started000000002413
Treated000000002413
Completed0000000034
Not completed00000000219
Withdrew: Lost to follow-up0000000010
Withdrew: Withdrawal by subject0000000023
Withdrew: Transitioned to a separate extension study00000000186

Outcome measures

PrimaryPercentage of Participants in Cohort 1 Achieving Clinical Remission

The 3-component Modified Mayo Score (MMS) ranges from 0 to 9 and is composed of endoscopic assessment, rectal bleeding (RB), and stool frequency (SF) subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Cohort 1 Achieving Clinical Remission
Percentage of participantsCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 Achieving Clinical Remission26.51.5
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 25.0 · 95% CI 11.8 to 36.595% CI is estimated using Newcombe method for risk difference.
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who experienced at least one AE is reported.

Time frame:
Up to ~14 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of participantsAll Cohorts (Cohort 1 & Cohort 2) TulisokibartAll Cohorts (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Experienced an Adverse Event (AE)45.643.2
PrimaryPercentage of Participants Who Discontinued Due to an AE

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who discontinued due to an AE is reported.

Time frame:
Up to ~14 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Due to an AE
Percentage of participantsAll Cohorts (Cohort 1 & Cohort 2) TulisokibartAll Cohorts (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Discontinued Due to an AE1.13.4
SecondaryPercentage of Participants in Cohort 1 With Endoscopic Improvement

The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of the MMS of ≤ 1 with no friability. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Cohort 1 With Endoscopic Improvement
Percentage of participantsCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 With Endoscopic Improvement36.86.0
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 30.8 · 95% CI 17.4 to 43.295% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants in Cohort 1 Achieving Clinical Response

The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined as a reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Cohort 1 Achieving Clinical Response
Percentage of participantsCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 Achieving Clinical Response66.222.4
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 43.8 · 95% CI 27.4 to 56.995% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Remission

The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Remission
Percentage of participantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Remission31.610.8
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Cochran-Mantel-Haenszel · p = 0.0224 · Risk difference (rd): 20.8 · 95% CI 2.1 to 37.995% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants in Cohort 1 With Symptomatic Remission

RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Cohort 1 With Symptomatic Remission
Percentage of participantsCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 With Symptomatic Remission19.16.0
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = 0.0223 · Risk difference (rd): 13.1 · 95% CI 1.8 to 24.695% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants in Cohort 1 With Histologic Improvement

Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage
Percentage of Participants in Cohort 1 With Histologic Improvement
PercentageCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 With Histologic Improvement46.217.5
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = 0.0009 · Risk difference (rd): 28.6 · 95% CI 12.1 to 42.995% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Improvement

Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Improvement
Percentage of participantsCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Improvement30.83.5
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 27.3 · 95% CI 14.3 to 39.695% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Endoscopic Improvement

The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of MMS of ≤ 1 with no friability. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Endoscopic Improvement
Percentage of participantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Endoscopic Improvement36.818.9
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Risk difference (rd): 17.9 · 95% CI -2.4 to 36.495% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Response

The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined by reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Response
Percentage of ParticipantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Response55.332.4
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Risk difference (rd): 22.8 · 95% CI 0.4 to 42.295% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Symptomatic Remission

RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Symptomatic Remission
Percentage of participantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Symptomatic Remission21.110.8
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Risk difference (rd): 10.2 · 95% CI -6.9 to 26.995% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic Improvement

Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic Improvement
Percentage of participantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic Improvement55.626.7
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Risk difference (rd): 28.9 · 95% CI 5.0 to 48.395% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Improvement

Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Improvement
Percentage of participantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Improvement38.916.7
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Risk difference (rd): 22.2 · 95% CI 0.2 to 41.095% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Healing

Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Healing
Percentage of participantsCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Healing30.83.5
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 27.3 · 95% CI 14.3 to 39.695% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Healing

Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Healing
Percentage of participantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Healing38.916.7
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Risk difference (rd): 22.2 · 95% CI 0.2 to 41.095% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants in Cohort 1 With an Inflammatory Bowel Disease Questionnaire (IBDQ) Response

IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants in Cohort 1 were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Cohort 1 With an Inflammatory Bowel Disease Questionnaire (IBDQ) Response
Percentage of participantsCohort 1 TulisokibartCohort 1 Placebo
Percentage of Participants in Cohort 1 With an Inflammatory Bowel Disease Questionnaire (IBDQ) Response82.449.3
Statistical analysis
  • Cohort 1 Tulisokibart vs Cohort 1 Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 33.1 · 95% CI 17.2 to 46.895% CI is estimated using Newcombe method for risk difference.
SecondaryPercentage of Participants Who Are CDx+ (Cohorts 1 + 2) Who Had an IBDQ Response

IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.

Time frame:
Baseline and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Are CDx+ (Cohorts 1 + 2) Who Had an IBDQ Response
Percentage of participantsCDx+ (Cohort 1 & Cohort 2) TulisokibartCDx+ (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Are CDx+ (Cohorts 1 + 2) Who Had an IBDQ Response76.356.8
Statistical analysis
  • CDx+ (Cohort 1 & Cohort 2) Tulisokibart vs CDx+ (Cohort 1 & Cohort 2) Placebo · Risk difference (rd): 19.6 · 95% CI -1.7 to 38.795% CI is estimated using Newcombe method for risk difference.
PrimaryPercentage of Participants Who Had One or More Serious Adverse Events

Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Serious adverse events are defined as: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Life-threatening consequences; urgent intervention indicated, and death. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants experiencing a serious AE are presented.

Time frame:
Up to ~14 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had One or More Serious Adverse Events
Percentage of participantsAll Cohorts (Cohort 1 & Cohort 2) TulisokibartAll Cohorts (Cohort 1 & Cohort 2) Placebo
Percentage of Participants Who Had One or More Serious Adverse Events1.18.0

Adverse events

Collected over Up to approximately 43 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Tulisokibart0/68 (0%)0/68 (0%)14/68 (20.6%)
Cohort 1 Placebo0/67 (0%)6/67 (9%)10/67 (14.9%)
Cohort 2 Tulisokibart0/22 (0%)1/22 (4.5%)2/22 (9.1%)
Cohort 2 Placebo0/21 (0%)1/21 (4.8%)6/21 (28.6%)
Open-label Induction0/82 (0%)0/82 (0%)12/82 (14.6%)
Week 12 Responders: OLE 100 mg Tulisokibart0/41 (0%)3/41 (7.3%)23/41 (56.1%)
Week 12 Responders: OLE 250 mg Tulisokibart0/46 (0%)2/46 (4.3%)28/46 (60.9%)
Week 26 Responders: OLE 100 mg Tulisokibart0/31 (0%)0/31 (0%)16/31 (51.6%)
Week 26 Responders: OLE 250 mg Tulisokibart0/27 (0%)3/27 (11.1%)15/27 (55.6%)
Week 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg0/24 (0%)1/24 (4.2%)11/24 (45.8%)
Week 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg0/13 (0%)0/13 (0%)10/13 (76.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventCohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboOpen-label InductionWeek 12 Responders: OLE 100 mg TulisokibartWeek 12 Responders: OLE 250 mg TulisokibartWeek 26 Responders: OLE 100 mg TulisokibartWeek 26 Responders: OLE 250 mg TulisokibartWeek 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mgWeek 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg
Colitis ulcerativeGastrointestinal disorders0/685/670/220/210/821/411/460/310/270/240/13
Post procedural cellulitisInfections and infestations0/680/670/221/210/820/410/460/310/270/240/13
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/680/671/220/210/820/410/460/310/270/240/13
Umbilical herniaGastrointestinal disorders0/680/670/220/210/820/410/460/310/271/240/13
Intestinal stenosisGastrointestinal disorders0/680/670/220/210/820/410/460/311/270/240/13
Large intestine perforationGastrointestinal disorders0/680/670/220/210/820/410/460/311/270/240/13
Clostridium difficile infectionInfections and infestations0/680/670/220/210/820/410/460/311/270/240/13
ConcussionInjury, poisoning and procedural complications0/680/670/220/210/821/410/460/310/270/240/13
Facial bones fractureInjury, poisoning and procedural complications0/680/670/220/210/821/410/460/310/270/240/13
Radius fractureInjury, poisoning and procedural complications0/680/670/220/210/821/410/460/310/270/240/13
Most frequent other events
Showing 10 of 29
Most frequent other events
EventCohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboOpen-label InductionWeek 12 Responders: OLE 100 mg TulisokibartWeek 12 Responders: OLE 250 mg TulisokibartWeek 26 Responders: OLE 100 mg TulisokibartWeek 26 Responders: OLE 250 mg TulisokibartWeek 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mgWeek 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg
Colitis ulcerativeGastrointestinal disorders1/681/670/223/213/8211/4117/4612/3113/272/242/13
Upper respiratory tract infectionInfections and infestations1/683/671/221/212/827/416/462/312/275/241/13
NasopharyngitisInfections and infestations1/682/671/221/213/823/415/461/311/273/241/13
HeadacheNervous system disorders3/683/670/220/212/821/411/460/311/273/240/13
COVID-19Infections and infestations5/683/670/221/212/824/412/460/312/272/240/13
Back painMusculoskeletal and connective tissue disorders2/680/670/220/210/821/411/463/310/271/240/13
TinnitusEar and labyrinth disorders0/680/670/220/210/820/410/460/311/272/240/13
Atrial fibrillationCardiac disorders0/680/670/220/210/820/410/460/310/270/241/13
Anal pruritusGastrointestinal disorders0/680/670/220/210/820/410/460/310/270/241/13
Umbilical herniaGastrointestinal disorders0/680/670/220/210/820/410/460/310/270/241/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
Mean40.4 ± 14.442.2 ± 16.338.1 ± 18.238.5 ± 11.440.6 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
Female342910477
Male34381217101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
Hispanic or Latino42118
Not Hispanic or Latino60621919160
Unknown or Not Reported432110
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
American Indian or Alaska Native00000
Asian11204
Native Hawaiian or Other Pacific Islander00000
Black or African American02002
White65571720159
More than one race01001
Unknown or Not Reported263112
CDx+/CDx-
CDx+/CDx-(Participants)Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
CDx+1616222175
CDx-525100103
Body Mass Index (BMI)
Body Mass Index (BMI)(Weight (kg) / [Height (m)]^2)Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
Mean25.71 ± 7.02925.52 ± 5.03325.11 ± 4.53926.37 ± 5.51825.63 ± 5.845
Height
Height(Centimeters (cm))Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
Mean169.91 ± 9.798172.61 ± 9.185172.31 ± 8.729173.26 ± 8.418171.61 ± 9.317
Weight
Weight(Kilograms (kg))Cohort 1 TulisokibartCohort 1 PlaceboCohort 2 TulisokibartCohort 2 PlaceboTotal
Mean73.89 ± 19.65376.59 ± 18.48274.62 ± 14.98579.36 ± 14.98475.64 ± 18.135

10 further baseline measures are reported on the registry.

08

Study locations

88 sites
  • Prometheus Biosciences Selected Center
    Mobile, Alabama 36608, United States
  • Prometheus Biosciences Selected Site
    Phoenix, Arizona 85006, United States
  • Prometheus Biosciences Selected Site
    Sun City, Arizona 85351, United States
  • Prometheus Biosciences Selected Site
    Los Angeles, California 90045, United States
  • Prometheus Biosciences Selected Site
    Los Angeles, California 90048, United States
  • Prometheus Biosciences Selected Site
    San Diego, California 92037, United States
  • Prometheus Biosciences Selected Site
    Bristol, Connecticut 06010, United States
  • Prometheus Biosciences Selected Site
    Atlanta, Georgia 30010, United States
  • Prometheus Biosciences Selected Site
    Arlington Heights, Illinois 60005, United States
  • Prometheus Biosciences Selected Site
    Glenview, Illinois 60026, United States
  • Prometheus Biosciences Selected Site
    Gurnee, Illinois 60031, United States
  • Prometheus Biosciences Selected Site
    Kansas City, Kansas 66160, United States
  • Prometheus Biosciences Selected Site
    Liberty, Kansas 64098, United States
  • Prometheus Biosciences Selected Site
    Baton Rouge, Louisiana 70809, United States
  • Prometheus Biosciences Selected Site
    Chevy Chase, Maryland 20815, United States
  • Prometheus Biosciences Selected Site
    Chesterfield, Michigan 48047, United States
  • Prometheus Biosciences Selected Site
    Lebanon, New Hampshire 03756, United States
  • Prometheus Biosciences Selected Site
    New York, New York 10029, United States
  • Prometheus Biosciences Selected Site
    New York, New York 10065, United States
  • Prometheus Biosciences Selected Site
    Dublin, Ohio 43016, United States
  • Prometheus Biosciences Selected Site
    Germantown, Tennessee 38138, United States
  • Prometheus Biosciences Selected Site
    Bedford, Texas 76022, United States
  • Prometheus Biosciences Selected Site
    Lubbock, Texas 79424, United States
  • Prometheus Biosciences Selected Site
    Mansfield, Texas 76063, United States
  • Prometheus Biosciences Selected Site
    San Antonio, Texas 78229, United States
  • Prometheus Biosciences Selected Site
    Southlake, Texas 76092, United States
  • Prometheus Biosciences Selected Site
    Tyler, Texas 75702, United States
  • Prometheus Biosciences Selected Site
    Charlottesville, Virginia 22903, United States
  • Prometheus Biosciences Selected Site
    Tacoma, Washington 98405, United States
  • Prometheus Biosciences Selected Site
    Woodville, Adelaide, Australia
  • Prometheus Biosciences Selected Site
    Kingswood, New South Wales 2747, Australia
  • Prometheus Biosciences Selected Site
    Old Toongabbie, New South Wales NSW 2146, Australia
  • Prometheus Biosciences Selected Site
    South Brisbane, Queensland 4101, Australia
  • Prometheus Biosciences Selected Site
    Woolloongabba, Queensland 4102, Australia
  • Prometheus Biosciences Selected Site
    Adelaide, South Australia 5000, Australia
  • Prometheus Biosciences Selected Site
    Fitzroy, Victoria VIC 3065, Australia
  • Prometheus Biosciences Selected Site
    Melbourne, Victoria VIC 3065, Australia
  • Prometheus Biosciences Selected Site
    Leuven, 3000, Belgium
  • Prometheus Biosciences Selected Site
    Liège, 4000, Belgium
  • Prometheus Biosciences Selected Site
    Calgary, Alberta T2N 4Z6, Canada
  • Prometheus Biosciences Selected Site
    Vancouver, British Columbia V6Z2K5, Canada
  • Prometheus Biosciences Selected Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Prometheus Biosciences Selected Site
    North York, Ontario M6A 3B4, Canada
  • Prometheus Biosciences Selected Site
    Brno, Czechia
  • Prometheus Biosciences Selected Site
    Hradec Králové, Czechia
  • Prometheus Biosciences Selected Site
    Olomouc, 779 00, Czechia
  • Prometheus Biosciences Selected Site
    Slaný, Czechia
  • Prometheus Biosciences Selected Site
    Clichy, 92110, France
  • Prometheus Biosciences Selected Site
    Lille, 59037, France
  • Prometheus Biosciences Selected Site
    Nice, 06202, France
  • Prometheus Biosciences Selected Site
    Pierre-Bénite, 69495, France
  • Prometheus Biosciences Selected Site
    Saint-Priest-en-Jarez, 42270, France
  • Prometheus Biosciences Selected Site
    Vandœuvre-lès-Nancy, 54511, France
  • Prometheus Biosciences Selected Site
    Tbilisi, Georgia
  • Prometheus Biosciences Selected Site
    Győr, Győr-Moson-Sopron 9024, Hungary
  • Prometheus Biosciences Selected Site
    Békéscsaba, 5600, Hungary
  • Prometheus Biosciences Selected Site
    Budapest, 1062, Hungary
  • Prometheus Biosciences Selected Site
    Budapest, 1088, Hungary
  • Prometheus Biosciences Selected Center
    Budapest, 1135, Hungary
  • Prometheus Biosciences Selected Site
    Afula, 18341, Israel
  • Prometheus Biosciences Selected Site
    Beersheba, 84100, Israel
  • Prometheus Biosciences Selected Site
    Holon, 58100, Israel
  • Prometheus Biosciences Selected Site
    Jerusalem, 91031, Israel
  • Prometheus Biosciences Selected Site
    Petah Tikva, 49414, Israel
  • Prometheus Biosciences Selected Site
    Bologna, Emilia-Romagna 40138, Italy
  • Prometheus Biosciences Selected Site
    Milan, Milan 20132, Italy
  • Prometheus Biosciences Selected Site
    Milan, Milan 20157, Italy
  • Prometheus Biosciences Selected Site
    Roma, Rome 00168, Italy
  • Prometheus Biosciences Selected Site
    Poznan, Greater Poland Voivodeship 61-441, Poland
  • Prometheus Biosciences Selected Site
    Włocławek, Kuuavian-Pomeranian 87-800, Poland
  • Prometheus Biosciences Selected Site
    Krakow, Lesser Poland Voivodeship 31-009, Poland
  • Prometheus Biosciences Selected Site
    Wroclaw, Lower Silesian Voivodeship 40-211, Poland
  • Prometheus Biosciences Selected Site
    Wroclaw, Lower Silesian Voivodeship 540144, Poland
  • Prometheus Biosciences Selected Site
    Warsaw, Masovia 04-730, Poland
  • Prometheus Biosciences Selected Site
    Katowice, Silesian 40-211, Poland
  • Prometheus Biosciences Selected Site
    Krakow, Poland
  • Prometheus Biosciences Selected Site
    Lodz, 93-357, Poland
  • Prometheus Biosciences Selected Site
    Lublin, 20-362, Poland
  • Prometheus Biosciences Selected Site
    Lublin, 20-607, Poland
  • Prometheus Biosciences Selected Site
    Rzeszów, Poland
  • Prometheus Biosciences Selected Site
    Sopot, Poland
  • Prometheus Biosciences Selected Site
    Szczecin, Poland
  • Prometheus Biosciences Selected Site
    Torun, Poland
  • Prometheus Biosciences Selected Site #2
    Warsaw, Poland
  • Prometheus Biosciences Selected Site
    Warsaw, Poland
  • Prometheus Biosciences Selected Site
    Wroclaw, Poland
  • Prometheus Biosciences Selected Site
    Prescot, Merseyside L34 1BH, United Kingdom
  • Prometheus Biosciences Selected Sites
    London, E11 1NR, United Kingdom
09

References and documents

Publications

  • Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempinski R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 Sep 26;391(12):1119-1129. doi: 10.1056/NEJMoa2314076. PubMed 39321363 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2023, 22 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 22 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 9, 2021
StartActual
Jul 14, 2021
Primary completionActual
Jun 6, 2023
CompletionActual
Jul 14, 2025
Results first posted
Jun 27, 2024
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04996797
Responsible party
Sponsor
First posted
Aug 9, 2021
Start date
Jul 14, 2021
Primary completion
Jun 6, 2023
Completion
Jul 14, 2025
Results posted
Jun 27, 2024
Last update
Sep 1, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion